Stratum corneum collected by tape stripping from 10 and 24 subjects with cutaneous T-cell lymphomas (CTCL) or psoriasis, respectively, were compared using quantitative label-free mass spectrometry analysis. A non-supervised statistical analysis (Posneg NMF) based on 352 differentially expressed proteins in both CTCL and psoriasis samples was able to separate the two disease groups and finally able to identify a set of 112 proteins that contributed most and significantly to the separation when compared to non-lesional samples. In addition, Luminex assay revealed that the increase in the amount of chemokines related to the inflammatory response, and immune cell infiltration and recruitment in lesional stratum corneum in CTCL, including CXCL8, CXCL9, CXCL10, CCL27, TNF and sICAM-1 was in agreement with published data on entire skin biopsies. Proteome analysis using quantitative methods including mass spectrometry and Luminex technology offered the possibility to investigate the relevant protein signature in CTCL and may be helpful to diagnose and investigate the efficacy of treatments in clinical investigations using non-invasive methods in future.
| BACKG ROU N D
Cutaneous T-cell lymphomas (CTCL) are a group of skin lymphomas with different clinical and histological features including mycosis fungoides (MF) and its leukaemic variant, Sezary syndrome (SS). [1] Signs include patches, plaques, erythroderma (redness), itching and tumors, and the disease is often associated with pruritus. However, overlaps exist between the clinical presentation of CTCL and other inflammatory skin diseases such as psoriasis, atopic dermatitis, chronic eczema or other benign inflammatory dermatoses, such that diagnosis and treatment may be delayed. [2] Transcription expression profiling was performed and transcripts were identified as putative markers of CTCL and may be useful in the diagnosis of this disease. [3] Recently, a non-invasive tape stripping procedure was proposed to characterize psoriasis which is useful for drug profiling in clinical investigations [4] and other skin diseases. [5] [6] [7] 
| QUE S TIONS ADDRE SS ED
Can non-invasive stratum corneum sampling characterize CTCL lesions and can it be used to precisely diagnose and differentiate it from psoriasis?
| E XPERIMENTAL DE S I G N
In this study, we performed the quantification of proteins present in human lesional and non-lesional stratum corneum (SC) collected by a non-invasive tape stripping procedure in 10 subjects with CTCL (chest and forearm) and 24 subjects with psoriasis (forearm) as described in the Material and Methods (Supplementary files). Labelfree quantitative mass spectrometry analysis (MS) and Luminex assays were used to assess inflammatory events, and statistical analysis including Posneg NMF [8] was performed as described in the Material and Methods (supporting information). Biological processes were analysed using David Tools software.
| RE SULTS
Using label-free quantitative mass spectrometry analysis, 431 proteins were identified in the SC in CTCL lesions and 543 proteins were identified in the SC in psoriasis lesions after normalization (Tables S1 and S2 ). We performed a non-supervised statistical analysis, based on 352 proteins differentially expressed compared to non-lesional samples that were detected in both CTCL and psoriasis samples. Posneg NMF [8] was applied on the matrix to identify gene signatures of up-and down-regulated genes. Finally, a good separation between the two disease groups was observed with few classification errors. This was based on a set of 112 proteins which significantly contributed to the separation ( Figure 1 and Table S3 ).
From this set of proteins, biological processes were analysed using David Tools software for the clusters identified (Table S4) . Clusters 1 and 2 regrouped most of the psoriasis samples and biological processes known to be involved in this disease. Cluster 3 containing modulated proteins is able to differentiate CTCL samples and pointed to cytoskeletal modifications as a significantly impacted biological process (Table S5 ). The level of proteins identified in cluster 3 in non-lesional and lesional SC in all CTCL and psoriasis subjects is indicated in Figures S1 and S2 , respectively. For CTCL, all proteins identified in cluster 3 were increased in lesional SC, except for phospholipase B-like 2 (PLBD2). In addition, in order to identify diseases markers, we performed a comparison between lesional and non-lesional SC in CTCL and psoriasis samples using Genedata software (see Tables S6, S7 (Tables S9 and S10) . A restricted number of chemokines and cytokines were found to be modulated in lesional SC in CTCL samples (Table 1 and Tables S9 and S10 ). Importantly, our observations were in agreement with published data on entire skin biopsies, except for interleukin 1a (IL1alpha) where the increase we observed was lower compared to previous data. [9] The observed increase in chemokines in lesional SC in CTCL samples is related to the inflammatory response, and immune cell infiltration and recruitment including CXCL10 and CXCL9 that target lymphocytes. [10, 11] CXCL8 is suggested to play a minor role in CTCL [11] but probably associated with epidermal necrosis and myeloperoxidase, a neutrophil marker. The increased CCL27 observed in lesional SC confirm the pivotal role of CCL27-CCR10 interactions in T cell-mediated skin inflammation in CTCL. [12, 13] Interestingly, TNF was also found to be increased and was described as an inducer of CCL27 production. [14] A moderate
and not quite significant increase in VEGF was observed supporting disease progression. [15] sICAM-1 was found to be elevated in CTCL in lesional SC. Interestingly, imiquimod, a FDA-approved ligand of Toll-like receptor 7 has been shown to reduce the level of secretion of sICAM-1 and was used off-label for the treatment of early stage CTCL. The increase in the MIF content contributing to the innate immune response to bacterial pathogens was observed by MS in lesional SC and was confirmed using Luminex assay ( Table 1) .
As indicated in Table S11 , most of the cytokines and chemokines, which show an increased in SC in CTCL samples, were also previously reported to be modulated in psoriasis lesions. CXCL1, CXCL8, CXCL10 and sICAM-1 were recently identified in psoriasis as putative markers useful for drug profiling. [4] These markers were quantified in the same manner in CTCL and psoriasis samples (Table S12) and used in the Posneg NMF approach ( Figure S5 ). The content of these proteins in lesional CTCL and psoriasis samples was compared to non-lesional SC and was found to be different (Table S12 right panel LS/NLS ratio). We found that these proteins participate to the separation between CTCL and psoriasis samples.
| CON CLUS ION
Proteome analysis using label-free MS was able to identify 112 proteins in SC which differentiate CTCL from psoriasis (with a small overlap). However, Luminex analysis of 66 cytokines, chemokines and growth factors cannot noticeably differentiate between these two diseases. The SC protein signature is relevant and may be helpful in future to diagnose CTCL and to investigate the efficacy of treatments in clinical investigations using noninvasive methods. Table S3 , S and L: stability and leverage, respectively. (B). Graphical 3-dimensional representation showing separation between the two pathologies. The axes correspond to the 3 NMF components, each being specific to a subpopulation, CTCL samples: red circle; psoriasis samples: blue square. (C) Level of actin 4, GST01 and MIF identified using mass spectrometry in CTCL and psoriasis in non-lesional and lesional stratum corneum using Genedata software analysis (see supporting information)
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We thank Luigi Russo for technical assistance and Florence Joly for helpful discussions. We are grateful for helpful comments provided by Dc Claire Wilson. TA B L E 1 Level of cytokines significantly modulated in stratum corneum in CTCL. Cytokines, chemokines and growth factors were quantified using Luminex multiplex assay from non-lesional and lesional stratum corneum protein extracts. The amounts were normalized with the total protein content (pg/mg). Mean values were obtained from 10 subjects in CTCL. Modulations of cytokines and chemokines were compared with results reported in entire skin biopsies and blood. Quantification of additional cytokines and chemokines is described in supplementary files. TNF was determined using a high sensitivity assay. Comparison with published data on psoriasis reported previously [4] was in supporting information (Table S11) . Comparison for CXCL1, CXCL8, CXCL10 and sICAM-1 is also shown in Table S9 [16] and skin [10, 11] Involved in the preferential infiltration of T cells (CD4 + ) CCL27 (C-TACK) Q9Y4X3 811 88 9.2 ** ↑ in blood [17] [18] [19] and skin [17] Recruitment of atypical T cells to the skin CXCL9 (Mig) Q07325 424 50 8.4 ** ↑ in skin [11] Involved in the preferential infiltration of activated T cells [20] and cell lines [21] Chemoattractant involved in epidermotropism of T cells [9] Produced by activated macrophages, IL-1 stimulates thymocyte proliferation, B-cell maturation and proliferation, and fibroblast growth factor activity Alexandre Genette 
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Additional supporting information may be found online in the Supporting Information section at the end of the article.
Figure S1 level of proteins identified in cluster 3 in non-lesional (NLS)
and lesional (LS) stratum corneum (SC) in CTCL using mass spectrometry. Gene data search: One-way ANOVA was used to calculate the P-value based on the transformed values (log 2). The dataset of the Genedata analysis used the following parameters: Anova P-value ≤0.05, Max fold change ≥2; at least 2 peptides for quantification and a power >0.8. For each subjects level of protein was indicated in the Table S1 Figure S2 level of proteins identified in cluster 3 in non-lesional (NLS) and lesional (LS) stratum corneum (SC) in Psoriasis using mass spectrometry. Gene data search: One-way ANOVA was used to calculate the p-value based on the transformed values (log 2). The dataset of the Genedata analysis used the following parameters: Anova P-value ≤0.05, Max fold change ≥2; at least 2 peptides for quantification and a power >0.8. For each subjects level of protein was indicated in the Table S2 Figure S3 Level of proteins significantly modulated in CTCL in nonlesional (NLS) and lesional (LS) stratum corneum (SC) using Genedata software. Genedata search: One-way ANOVA was used to calculate the p-value based on the transformed values (log 2). The dataset of the Genedata analysis used the following parameters: Anova P-value ≤0.05, Max fold change ≥2; at least 2 peptides for quantification and a power >0.8. For each subjects level of protein was indicated in the Table S1 Figure S4 Level of proteins significantly modulated in Psoriasis in non-lesional (NLS) and lesional (LS) stratum corneum (SC) using Genedata software. Genedata search: One-way ANOVA was used to calculate the P-value based on the transformed values (log 2). The dataset of the Genedata analysis used the following parameters:
Anova P-value ≤0.05, Max fold change ≥2; at least 2 peptides for quantification and a power >0.8. For each subjects level of protein was indicated in the Table S2 Figure S5 NMF analysis of CXCL1, siCAM-1, CXCL10 and CXCL8.
Quantification was performed using the same Luminex assay in CTCL and psoriasis. Fold change was calculated as indicated for MS analysis (see also 
L E T T E R : M O U S E M U T A N T S W I T H A B S E N T S K I N P H E N O T Y P E
IL-17A/F in
| BACKG ROU N D
IL-17 is a proinflammatory cytokine secreted by CD4 + Th17 and γδ
T cells as well as a subset of innate lymphoid cells (ILC3)
. [1] The main function of IL-17 is to induce the production of various cytokines, for example, IL-1 and TNFα, and chemokines leading to the recruitment of neutrophils and monocytes to sites of T-cell activation. [1] [2] [3] IL-17
plays an important role in various diseases, for example, rheumatoid arthritis, psoriasis, multiple sclerosis and in defence mechanisms against extracellular microorganisms.
[1]
Leishmaniasis, a parasitic skin disease with high rates of morbidity and mortality, [4] is caused by various Leishmania spp. During blood feeding, the promastigote life form of the parasite is transmit- to IFNγ-producing cells. [5] IFNγ-producing Th1/Tc1 cells then relocate to sites of infection and activate infected MΦ finally to kill the intracellular parasite. [5] In immunocompetent humans as well as in C57BL/6 mice, infections with Leishmania (L.) major result in Th1/ Tc1-driven immune responses with self-healing lesions, high levels of IFNγ and IL-12p40 along with long-lasting immunity. In contrast, in susceptible BALB/c mice and immunosuppressed humans, infections with L. major leads to Th2/Treg/Th17-predominant immune responses with high levels of secreted IL-4, IL-10 and IL-17A. [3, 5, 6] Previously, we observed that L. major-infected BALB/c mice exhibit higher levels of secreted IL-17A from CD4 T cells [3] compared to infected C57BL/6 mice. Additionally, IL-17A-deficient BALB/c mice 
